{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:02:09Z","timestamp":1780153329434,"version":"3.54.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":101,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-NESTLE2022MS-0362"],"award-info":[{"award-number":["Y-NESTLE2022MS-0362"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Scholars Fostering Fund of the First Affiliated Hospital with Nanjing Medical University","award":["PY202424"],"award-info":[{"award-number":["PY202424"]}]},{"name":"Center for Medical and Health Technology Development, National Health Commission","award":["WKZX2024CX102203"],"award-info":[{"award-number":["WKZX2024CX102203"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer is one of the most lethal malignancies, with limited therapeutic options. In this exploratory trial, we aimed to evaluate the efficacy and safety of nanoparticle polymeric micellar paclitaxel (pm-Pac) combined with gemcitabine as first-line treatment for metastatic pancreatic cancer (mPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-one patients with histologically or cytologically confirmed mPC were enrolled in this study. The primary endpoint was progression-free survival (PFS). Meanwhile, the secondary endpoints included the objective response rate (ORR), overall survival, disease control rate (DCR), duration of response (DOR), and safety of combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median PFS was 7.4\u2009months (95% confidence interval [CI]: 5.4\u20139.4\u2009months). The ORR and DCR were 52.4% (95% CI: 29.1%\u201375.7%) and 95.2% (95% CI: 85.3%\u2013100%), respectively. Amongst patients who achieved partial response, the median DOR was 4.8\u2009months (95% CI: 1.5\u20138.1\u2009months). No treatment-related deaths were reported. Grade 3\u20134 adverse events (AEs) occurred in 81.0% of patients, with increased \u03b3-glutamyltransferase levels (38.1%), neutropenia (33.3%), and leukocytopenia (28.6%) being the most frequent AEs. Low SERPINB3 and SERPINB4 expression was correlated with prolonged PFS, accompanied by the significant downregulation of gene sets involved in DNA replication, nonsense-mediated mRNA decay, and protein translation in long-PFS tumours. Tumour immune microenvironment analysis revealed that patients with short PFS had increased levels of common lymphoid progenitors and decreased populations of mature B and T lymphocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of pm-Pac and gemcitabine as first-line therapy for mPC exhibited favourable tolerability and clinical efficacy. However, larger randomized\u2013controlled trials are needed to validate these preliminary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>www.chictr.org.cn, ChiCTR2300078861<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gastro\/goag034","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:44:30Z","timestamp":1774442670000},"source":"Crossref","is-referenced-by-count":0,"title":["First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study"],"prefix":"10.1093","volume":"14","author":[{"given":"Nan","family":"Lyu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishu","family":"Wei","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipeng","family":"Lu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Chen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Gao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc. Geneseeq Research Institute, , Nanjing, Jiangsu, 211800, P. R.","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc. Geneseeq Research Institute, , Nanjing, Jiangsu, 211800, P. R.","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital with Nanjing Medical University Pancreas Center, , 300 Guangzhou Road , Nanjing, Jiangsu, 210029,","place":["China"]},{"name":"Sir Run Run Hospital, Nanjing Medical University Pancreas Center, , Nanjing, Jiangsu, 211100, P. R.","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"2026053010374577100_goag034-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026053010374577100_goag034-B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3322\/caac.21626","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026053010374577100_goag034-B3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"Pourshams","year":"2019","journal-title":"The Lancet Gastroenterol Hepatol"},{"key":"2026053010374577100_goag034-B4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(23)00516-8","article-title":"Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients","volume":"25","author":"Gyawali","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026053010374577100_goag034-B5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12916-018-1215-3","article-title":"Pancreatic cancer: challenges and opportunities","volume":"16","author":"Zhu","year":"2018","journal-title":"BMC Med"},{"key":"2026053010374577100_goag034-B6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"2026053010374577100_goag034-B7","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.21873\/anticanres.13026","article-title":"Targeted therapies for pancreatic cancer and hurdles ahead","volume":"38","author":"Aslan","year":"2018","journal-title":"Anticancer Res"},{"key":"2026053010374577100_goag034-B8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann of Oncol"},{"key":"2026053010374577100_goag034-B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081622","article-title":"Neoadjuvant therapy of pancreatic cancer: definitions and benefits","volume":"18","author":"Heinrich","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026053010374577100_goag034-B10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2026053010374577100_goag034-B11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J of Med"},{"key":"2026053010374577100_goag034-B12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/nejmoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J of Med"},{"key":"2026053010374577100_goag034-B13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/IJN.S372961","article-title":"Paclitaxel has a reduced toxicity profile in healthy rats after polymeric micellar nanoparticle delivery","volume":"18","author":"Lu","year":"2023","journal-title":"Int J Nanomed"},{"key":"2026053010374577100_goag034-B14","first-page":"603","article-title":"Tissue distribution of paclitaxel micelle and paclitaxel injection in tumorbearing mice","volume":"30","author":"Han","year":"2011","journal-title":"Chin J New Drugs Clin Remedies"},{"key":"2026053010374577100_goag034-B15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10637-017-0506-4","article-title":"Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies","volume":"36","author":"Shi","year":"2018","journal-title":"Invest New Drugs"},{"key":"2026053010374577100_goag034-B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","article-title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial","volume":"32","author":"Shi","year":"2021","journal-title":"Ann Oncol"},{"key":"2026053010374577100_goag034-B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford, England\u202f: 1990)"},{"key":"2026053010374577100_goag034-B18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"key":"2026053010374577100_goag034-B19","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2024"},{"key":"2026053010374577100_goag034-B20","doi-asserted-by":"publisher","first-page":"6318","DOI":"10.1158\/0008-5472.CAN-14-0798","article-title":"SCCA1\/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling","volume":"74","author":"Sheshadri","year":"2014","journal-title":"Cancer Res"},{"key":"2026053010374577100_goag034-B21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semcdb.2016.09.005","article-title":"SERPINB3 and B4: from biochemistry to biology","volume":"62","author":"Sun","year":"2017","journal-title":"Seminars in Cell Dev Biol"},{"key":"2026053010374577100_goag034-B22","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1038\/ncomms4729","article-title":"Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3\/B4","volume":"5","author":"Catanzaro","year":"2014","journal-title":"Nat Commun"},{"key":"2026053010374577100_goag034-B23","doi-asserted-by":"publisher","first-page":"113434","DOI":"10.1016\/j.celrep.2023.113434.SERPINB3-MYC","article-title":"SERPINB3-MYC axis induces the basal-like\/squamous subtype and enhances disease progression in pancreatic cancer","volume":"42","author":"Moreno","year":"2023","journal-title":"Cell Rep"},{"key":"2026053010374577100_goag034-B24","doi-asserted-by":"publisher","first-page":"e1005787","DOI":"10.1371\/journal.pgen.1005787","article-title":"Chronic DNA replication stress reduces replicative lifespan of cells by TRP53-dependent, microRNA-assisted MCM2-7 downregulation","volume":"12","author":"Bai","year":"2016","journal-title":"PLoS Genet"},{"key":"2026053010374577100_goag034-B25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s13046-021-02192-2","article-title":"Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy","volume":"40","author":"Bongiorno","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026053010374577100_goag034-B26","doi-asserted-by":"publisher","first-page":"349067","DOI":"10.1155\/2013\/349067","article-title":"Lymphoid progenitor cells from childhood acute lymphoblastic leukemia are functionally deficient and express high levels of the transcriptional repressor Gfi-1","volume":"2013","author":"Purizaca","year":"2013","journal-title":"Clin Dev Immunol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag034\/68198545\/goag034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag034\/68198545\/goag034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T14:37:57Z","timestamp":1780151877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag034\/8666106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag034","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag034"}}